AstraZeneca · 14 hours ago
Data Sciences and Quantitative Biology Intern, Master’s and PhD Students
AstraZeneca is seeking Master’s and PhD level students for a 10-week internship role in Data Sciences and Quantitative Biology. The intern will be responsible for data integration and curation, performing analyses and predictive modeling, and creating visualizations and reports to communicate findings to stakeholders.
BiopharmaBiotechnologyHealth CareMedicalPharmaceuticalPrecision Medicine
Responsibilities
Data integration and curation: Aggregate data, QC, and harmonize internal and external chemical proteomics datasets (e.g. covalent datasets, molecular glues, chemoproteomics hits, compound/warhead annotations) into the in-house database
Insights and predictive modeling: Perform analyses and prototype models to predict drug–target affinity and generate prioritization scores for nominated targets
Visualization and reporting: Create dashboards/figures to communicate findings and deliver concise summaries to stakeholders
Qualification
Required
Master's and PhD level students majoring in Computational Biology, Bioinformatics, Computer Science, Machine Learning/Deep Learning or a related discipline
Candidates must have an expected graduation date after August 2026
Proficiency in programming in R and/or Python for data analysis, with familiarity in machine learning and deep learning methods and framework
Comfortability working with SQL relational databases (for example, PostgreSQL, MySQL, or SQLite) to query and integrate data is required
Ability to report onsite to Waltham, MA (preferred) OR Gaithersburg, MD 3-5 days per week
US Work Authorization is required at time of application
Preferred
A basic understanding of molecular biology concepts relevant to chemical biology preferred
Familiarity with mass spectrometry–based proteomics and drug-discovery is a plus
Company
AstraZeneca
AstraZeneca is a pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines. It is a sub-organization of Investor.
Funding
Current Stage
Public CompanyTotal Funding
$5.26B2024-07-30Post Ipo Debt· $1.51B
2023-02-28Post Ipo Debt· $2.25B
2023-02-24Post Ipo Debt· $1.5B
Recent News
Business Standard India
2026-01-11
2026-01-11
2026-01-09
Company data provided by crunchbase